25.51  0.39 (1.55%)		04-14 10:20
Open: 25.15 High: 25.64 Volume: 98,434		Pre. Close: 25.12 Low: 25.1 Market Cap: 5,192(M)

Short term
Mid term
Targets	6-month :	31.23	1-year :	36.47
Resists	First :	26.73	Second :	31.23
Pivot price	24.72
Supports	First :	24.29	Second :	22.79
MAs	MA(5) :	25.08	MA(20) :	24.52
	MA(100) :	25.41	MA(250) :	20.22
MACD	MACD :	-0.2	Signal :	-0.3
%K %D	K(14,3) :	70.6	D(3) :	71.7
RSI	RSI(14): 52.5
52-week	High :	29.25	Low :	13.35

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ IMVT ] has closed below upper band by 19.6%. Bollinger Bands are 28.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	25.56 - 25.68	25.68 - 25.8
Low:	24.06 - 24.19	24.19 - 24.32
Close:	24.89 - 25.11	25.11 - 25.31

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Fri, 10 Apr 2026
Immunovant (IMVT) CLO sells 5,165 shares to cover RSU tax bill - Stock Titan

Fri, 10 Apr 2026
[Form 4] Immunovant, Inc. Insider Trading Activity - Stock Titan

Thu, 09 Apr 2026
Immunovant (IMVT) grants director Frank Torti RSUs and stock options - Stock Titan

Thu, 09 Apr 2026
Immunovant (IMVT) director receives RSU and stock option grants - Stock Titan

Thu, 09 Apr 2026
Immunovant (IMVT) grants director Douglas J. Hughes RSUs and stock options - Stock Titan

Thu, 09 Apr 2026
Immunovant (IMVT) director granted options and RSUs in new equity awards - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	204 (M)
Shares Float	77 (M)
Held by Insiders	57 (%)
Held by Institutions	54.2 (%)
Shares Short	16,570 (K)
Shares Short P.Month	16,950 (K)

EPS	-2.68
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.84
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-41.4 %
Return on Equity (ttm)	-69.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.4
Qtrly Earnings Growth	0 %
Operating Cash Flow	-423 (M)
Levered Free Cash Flow	-261 (M)

PE Ratio	-9.53
PEG Ratio	0
Price to Book value	5.24
Price to Sales	0
Price to Cash Flow	-12.24

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.